Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management

CNS oncology

Volumn 2, Issue 4, 2013, Pages 351-358

  Sahebjam, Solmaz ^a   McNamara, Mairéad G ^a   Mason, Warren P ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE; ISOCITRATE DEHYDROGENASE;

BRAIN NEOPLASMS; CHROMOSOME DELETION; DISEASE MANAGEMENT; GENETICS; HUMAN; LONGITUDINAL STUDY; MUTATION; OLIGODENDROGLIOMA;

BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CHROMOSOME DELETION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MANAGEMENT; DNA MODIFICATION METHYLASES; HUMANS; ISOCITRATE DEHYDROGENASE; LONGITUDINAL STUDIES; MUTATION; OLIGODENDROGLIOMA;

EID: 84925884906     PISSN: None     EISSN: 20450915     Source Type: Journal    
DOI: 10.2217/cns.13.26     Document Type: Review

References (0)